Originally published 2021-11-28.
In late November 2021, nine US senators who caucus with the Democrats wrote to President Joe Biden urging him to secure a waiver of intellectual property rules on Covid-19 vaccines at the World Trade Organization. Their goal was to let manufacturers in developing countries produce vaccines without needing permission from the companies that hold the patents.
It is worth being precise about the timeline. Biden had already announced US support for a temporary vaccine patent waiver in May 2021, so the letter did not win him over to the idea. What the senators complained about was the lack of progress since then, and they wanted the administration to push hard, especially with European allies, before a key WTO meeting. That meeting was then postponed days later because of the Omicron variant, and a much narrower deal was eventually agreed in June 2022.
Who signed the letter and what it asked for
The letter was led by Elizabeth Warren of Massachusetts, Tammy Baldwin of Wisconsin and independent Bernie Sanders of Vermont. The other six signers were:
- Sherrod Brown (Ohio)
- Ed Markey (Massachusetts)
- Chris Murphy (Connecticut)
- Richard Blumenthal (Connecticut)
- Ben Ray Luján (New Mexico)
- Jeff Merkley (Oregon)
They asked Biden to work with other world leaders, particularly in the European Union, to reach what they called a meaningful waiver that would boost vaccine production for poorer countries. According to The Hill, they warned that if the meeting failed, the WTO and the wealthy nations blocking the waiver
would keep losing credibility in the developing world.
Their central argument was about public money. The US and European governments had paid billions to drug companies to develop and distribute the leading vaccines, yet the resulting intellectual property was privately owned, a situation the senators described as pitting pharmaceutical profits against public health interests.
A waiver, they argued, would let factories in developing countries make vaccines locally, ease global shortages and reduce the risk of new variants emerging from large, uncontrolled outbreaks. The Hill also noted that 110 House Democrats had earlier written to Biden supporting the waiver.
What a TRIPS waiver actually is
The WTO's Agreement on Trade-Related Aspects of Intellectual Property Rights, known as TRIPS, requires member countries to protect patents, trade secrets and other intellectual property. In October 2020, India and South Africa proposed suspending parts of TRIPS for the duration of the pandemic, covering vaccines, tests, treatments and protective equipment.
Supporters, including many health charities and, by most counts, around 100 WTO members, said patents were one barrier to making more vaccines quickly. Opponents, including the pharmaceutical industry and several wealthy governments, especially in Europe, argued that patents were not the real bottleneck. In their view the shortages came from limited factory capacity, scarce raw materials and the specialised know-how needed to make complex products such as mRNA vaccines, none of which a waiver would supply on its own.
Both sides had a point. A waiver removes a legal obstacle, but it does not hand over manufacturing recipes, trained staff or equipment. That is why many experts said a waiver would work best alongside technology-transfer programmes, such as the WHO-backed mRNA hub set up in South Africa in 2021.
Omicron and the postponed WTO meeting
The senators' letter was timed for the WTO's 12th Ministerial Conference, due to open in Geneva on 30 November 2021. But on 24 November, South African scientists reported a new, heavily mutated variant to the World Health Organization. Two days later the WHO classified it as a variant of concern and named it Omicron.
Many countries, including the US, the UK and EU members, quickly restricted travel from southern Africa, even though the WHO advised against new travel bans. Omicron was soon detected in Europe and elsewhere. On 26 November, the WTO's General Council postponed the ministerial conference indefinitely, because travel restrictions and quarantine rules would have kept many ministers away from Geneva.
The postponement struck many observers as a grim irony: a meeting meant partly to tackle vaccine inequality was derailed by a variant that emerged in a region with low vaccination rates.
The deal agreed in June 2022
The ministerial conference finally met in June 2022. On 17 June, members adopted a decision that was far narrower than the original India and South Africa proposal. Its main points were:
- It covered vaccines only, not tests or treatments.
- Eligible developing countries could use patented ingredients and processes needed to make Covid-19 vaccines without the patent holder's consent, and without first having to negotiate a licence.
- It applies for five years, with the possibility of extension.
- Members were to decide within six months whether to extend it to tests and treatments.
Campaigners who had pushed for a broad waiver called the result disappointing, while the drug industry argued it was unnecessary. Talks on extending it to tests and treatments did not produce agreement by the deadline. By the time the decision passed, global vaccine supply had also improved considerably, so its practical effect was limited.
What the episode teaches
The patent waiver debate showed how hard it is to turn a broad principle, that lifesaving products should reach everyone, into a working global rule. Patents, factory capacity, know-how, financing and political will all mattered, and no single measure fixed the problem. Many of the same questions are now part of international discussions on how to share vaccines, tests and medicines fairly in a future pandemic.
For readers following the story, the key takeaways are simple: Biden backed a waiver in May 2021; senators pressed him in November 2021 to deliver one; Omicron delayed the decisive meeting; and the WTO agreed a limited, vaccines-only deal in June 2022.
Sources: The Hill: Senate Democrats call on Biden to push for vaccine patent waivers at WTO; WTO: MC12 postponed (26 November 2021); Fasken: limited TRIPS waiver for Covid-19 vaccines (June 2022); Wikipedia: Omicron variant.

COMMENTS